Sponsor:
Dr. George Luciuk
Code:
NCT07038746
Conditions
Hypersensitivity
Anaphylaxis
Eligibility Criteria
Sex: All
Age: 12+
Healthy Volunteers: Not accepted
Interventions
Inhaled Epinephrine
Brief summary:
Conditions
Hypersensitivity
Anaphylaxis
Study ID
NCT07038746
Start date
Aug 25, 2025
Status verified date
Aug, 2026
Completion date
Jan, 2027
Anticipated
Primary completion date
Dec, 2026
Anticipated
Eligibility Criteria
Sex: All
Age: 12+
Healthy Volunteers: Not accepted
Enrollment
100 participants
Anticipated
Intervention Model
Single group
Primary purpose
Treatment
Arms
experimental: Inhaled Epinephrine
Interventions
Inhaled Epinephrine
Primary outcome measure
Central contacts
Locations
Kokua Pharma Inc.
Recruiting
Richmond, British Columbia, Canada, V7C 5L9
Contacts
Principal Investigator:
George H. Luciuk, MD
Sponsor
Dr. George Luciuk
Last update posted
Aug 10, 2026
Last verified
Aug, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Dr. George Luciuk on 2026-08-10.